Limits...
Evaluation of tumour vaccine immunotherapy for the treatment of advanced non-small cell lung cancer: a systematic meta-analysis.

Wang M, Cao JX, Liu YS, Xu BL, Li D, Zhang XY, Li JL, Liu JL, Wang HB, Wang ZX - BMJ Open (2015)

Bottom Line: The results showed that the vaccine arm significantly extended primary endpoint median overall survival compared with control group (p<0.00001) (HR 0.760; 95% CI 0.644 to 0.896; p=0.001).Three subgroup patients with tumour vaccine at 1-year, 2-year and 3-year survival rates also gained significant benefits compared with their corresponding control group (p=0.0004, 0.03 and 0.19, respectively).A few severe adverse effects occurred in the tumour vaccine group, but fewer side effects were observed in the vaccine group compared with the control group (p<0.00001).

View Article: PubMed Central - PubMed

Affiliation: Biotherapy Center, General Hospital of Beijing Military Command, Beijing, People's Republic of China.

Show MeSH

Related in: MedlinePlus

Comparison of the objective response rate (ORR) between the tumour vaccine group and control group. The random effects model was used. Significant difference: p value <0.05.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4401843&req=5

BMJOPEN2014006321F3: Comparison of the objective response rate (ORR) between the tumour vaccine group and control group. The random effects model was used. Significant difference: p value <0.05.

Mentions: The vaccine treatment group showed a favourable result when subjected to analysis of the ORR which was denoted by complete response rates (CR) and partial rates (PR), compared with the corresponding control arm (OR 1.36, 95% CI 1.02 to 1.80, p=0.05).17182223 Indeed, vaccine immunotherapy generated a statistical difference compared with the control arm in four trials including 849 patients. Within the random effects model used in ORR analysis, no evidence of heterogeneity among the individual studies was observed (I2=15%, p=0.05; figure 3).


Evaluation of tumour vaccine immunotherapy for the treatment of advanced non-small cell lung cancer: a systematic meta-analysis.

Wang M, Cao JX, Liu YS, Xu BL, Li D, Zhang XY, Li JL, Liu JL, Wang HB, Wang ZX - BMJ Open (2015)

Comparison of the objective response rate (ORR) between the tumour vaccine group and control group. The random effects model was used. Significant difference: p value <0.05.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4401843&req=5

BMJOPEN2014006321F3: Comparison of the objective response rate (ORR) between the tumour vaccine group and control group. The random effects model was used. Significant difference: p value <0.05.
Mentions: The vaccine treatment group showed a favourable result when subjected to analysis of the ORR which was denoted by complete response rates (CR) and partial rates (PR), compared with the corresponding control arm (OR 1.36, 95% CI 1.02 to 1.80, p=0.05).17182223 Indeed, vaccine immunotherapy generated a statistical difference compared with the control arm in four trials including 849 patients. Within the random effects model used in ORR analysis, no evidence of heterogeneity among the individual studies was observed (I2=15%, p=0.05; figure 3).

Bottom Line: The results showed that the vaccine arm significantly extended primary endpoint median overall survival compared with control group (p<0.00001) (HR 0.760; 95% CI 0.644 to 0.896; p=0.001).Three subgroup patients with tumour vaccine at 1-year, 2-year and 3-year survival rates also gained significant benefits compared with their corresponding control group (p=0.0004, 0.03 and 0.19, respectively).A few severe adverse effects occurred in the tumour vaccine group, but fewer side effects were observed in the vaccine group compared with the control group (p<0.00001).

View Article: PubMed Central - PubMed

Affiliation: Biotherapy Center, General Hospital of Beijing Military Command, Beijing, People's Republic of China.

Show MeSH
Related in: MedlinePlus